October 3, 2012
In today's video, Brenton Flynn, Fool.com healthcare bureau chief, looks at one big pharma stock that may be going shopping: AstraZeneca (NYSE: AZN ) . With nearly half of the company's revenue at risk because of a looming patent cliff, it may have to shop around for something to fill that top-line gap. Abbott Labs (NYSE: ABT ) has similar patent cliff worries, as does Eli Lilly (NYSE: LLY ) .
Investors today should be on watch for any of these health care titans shopping around over the next few months.
When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining approval from the Food and Drug Administration for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.